Care este prețul pentru BioVaxys Technology Corp. (BIOV)

Prețul pentru BioVaxys Technology Corp. (BIOV) este $0.05137558

Care este capitalizarea de piață pentru BioVaxys Technology Corp. (BIOV)

Capitalizarea de piață pentru BioVaxys Technology Corp. (BIOV) este $1.50M

BioVaxys Technology Corp. (BIOV) Raport P/E

BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of vaccine platforms designed to combat both viral infections and cancer. The company's pipeline includes BVX-0320, a single-strain vaccine for SARS-CoV-2, and BVX-0918A, an experimental haptenized tumor cell vaccine targeting ovarian cancer. Additionally, BioVaxys offers CoviDTH, an immunodiagnostic tool to detect immune system activity in SARS-CoV-2-exposed patients. Further initiatives encompass Papilocare, aimed at HPV-dependent cervical lesions, along with BVX-0918C for cervical cancer, the HPV viral vaccine BVX-0204, and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys has established strategic collaborations, such as a bioproduction agreement with WuXi Biologics Limited to manufacture SARS-CoV-2 s-proteins crucial for BVX-0320 and CoviDTH. It also holds a research partnership with The Ohio State University, Wexner School of Medicine, focusing on BVX-0320, and has engaged Bioanalytical Systems, Inc. for preclinical toxicology evaluations of its CoviDTH immunodiagnostic. The company is headquartered in Vancouver, Canada.

An	Raport P/E	Schimbă
Nu sunt suficiente date pentru perioada selectată.

Raport P/E

Schimbă

Nu sunt suficiente date pentru perioada selectată.

Companie	P/E Ratio	Diferență P/E Ratio	Țara
Vertex Pharmaceuticals Incorporated VRTX.US	28.05	-	US
Argenx SE ARGX.US	30.62	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	19.30	-	BE

Companie

P/E Ratio

Diferență P/E Ratio

Țara